Soleno Therapeutics Management
Management criteria checks 1/4
Soleno Therapeutics' CEO is Anish Bhatnagar, appointed in Jan 2017, has a tenure of 7.83 years. total yearly compensation is $4.12M, comprised of 13.5% salary and 86.5% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth €2.45M. The average tenure of the management team and the board of directors is 0.8 years and 5.4 years respectively.
Key information
Anish Bhatnagar
Chief executive officer
US$4.1m
Total compensation
| CEO salary percentage | 13.5% |
| CEO tenure | 7.8yrs |
| CEO ownership | 0.1% |
| Management average tenure | less than a year |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$131m |
| Jun 30 2024 | n/a | n/a | -US$65m |
| Mar 31 2024 | n/a | n/a | -US$52m |
| Dec 31 2023 | US$4m | US$557k | -US$39m |
| Sep 30 2023 | n/a | n/a | -US$33m |
| Jun 30 2023 | n/a | n/a | -US$28m |
| Mar 31 2023 | n/a | n/a | -US$27m |
| Dec 31 2022 | US$1m | US$557k | -US$24m |
| Sep 30 2022 | n/a | n/a | -US$21m |
| Jun 30 2022 | n/a | n/a | -US$23m |
| Mar 31 2022 | n/a | n/a | -US$28m |
| Dec 31 2021 | US$4m | US$538k | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$31m |
| Jun 30 2021 | n/a | n/a | -US$31m |
| Mar 31 2021 | n/a | n/a | -US$28m |
| Dec 31 2020 | US$3m | US$504k | -US$25m |
| Sep 30 2020 | n/a | n/a | -US$36m |
| Jun 30 2020 | n/a | n/a | -US$27m |
| Mar 31 2020 | n/a | n/a | -US$30m |
| Dec 31 2019 | US$822k | US$470k | -US$31m |
| Sep 30 2019 | n/a | n/a | -US$16m |
| Jun 30 2019 | n/a | n/a | -US$19m |
| Mar 31 2019 | n/a | n/a | -US$16m |
| Dec 31 2018 | US$952k | US$460k | -US$12m |
| Sep 30 2018 | n/a | n/a | -US$16m |
| Jun 30 2018 | n/a | n/a | -US$17m |
| Mar 31 2018 | n/a | n/a | -US$13m |
| Dec 31 2017 | US$1m | US$446k | -US$12m |
Compensation vs Market: Anish's total compensation ($USD4.12M) is above average for companies of similar size in the German market ($USD1.90M).
Compensation vs Earnings: Anish's compensation has increased whilst the company is unprofitable.
CEO
Anish Bhatnagar (54 yo)
7.8yrs
Tenure
US$4,116,434
Compensation
Dr. Anish Bhatnagar, M.D. has been Chief Executive Officer and Director of Soleno Therapeutics, Inc. since 2017 and serves as its President and Chief Operating Officer. Prior to Soleno, Dr. Bhatnagar serve...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.8yrs | US$4.12m | 0.10% € 2.5m | |
| Chief Financial Officer | 5yrs | US$1.21m | 0.070% € 1.7m | |
| Senior Vice President of Regulatory Affairs | no data | US$1.03m | 0.091% € 2.2m | |
| General Counsel | less than a year | no data | no data | |
| Vice President of People | less than a year | no data | no data | |
| Senior Vice President of Clinical Operations | no data | US$821.67k | 0.027% € 644.9k | |
| Senior Vice President of Drug Development | 7.7yrs | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data | |
| Senior Vice President of Clinical Development | less than a year | no data | no data | |
| Chief Development Officer | less than a year | no data | no data | |
| Senior Vice President of Medical Affairs | less than a year | no data | no data |
0.8yrs
Average Tenure
55yo
Average Age
Experienced Management: 6XC's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.8yrs | US$4.12m | 0.10% € 2.5m | |
| Member of Advisory Board | less than a year | no data | no data | |
| Independent Director | 10.4yrs | US$111.87k | 0.021% € 489.9k | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Director | 5.9yrs | US$51.87k | 0.015% € 358.0k | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Director | 5.4yrs | US$102.87k | 0.016% € 387.9k | |
| Member of Advisory Board | no data | no data | no data | |
| Lead Independent Director | 1.3yrs | US$70.53k | 0% € 0 | |
| Chair of the Development Advisory Board | less than a year | no data | no data | |
| Member of Advisory Board | no data | no data | no data |
5.4yrs
Average Tenure
62yo
Average Age
Experienced Board: 6XC's board of directors are considered experienced (5.4 years average tenure).